Print this page    •   Back to Web version of article

Telaprevir Under Study for HIV/HCV Coinfection

By Liz Highleyman

Winter/Spring 2010

The investigational hepatitis C virus (HCV) protease inhibitor telaprevir -- the furthest along of the new directly targeted antiviral agents -- is now being tested in HIV/HCV coinfected individuals. The drug has demonstrated good antiviral activity in combination with pegylated interferon plus ribavirin in clinical trials of people with hepatitis C alone, and developer Vertex Pharmaceuticals plans to request FDA approval in the second half of this year. For further information, see "Open Clinical Trials."

Liz Highleyman ( is a freelance medical writer based in San Francisco.

This article was provided by San Francisco AIDS Foundation. It is a part of the publication Bulletin of Experimental Treatments for AIDS. You can find this article online by typing this address into your Web browser:

General Disclaimer: is designed for educational purposes only and is not engaged in rendering medical advice or professional services. The information provided through should not be used for diagnosing or treating a health problem or a disease. It is not a substitute for professional care. If you have or suspect you may have a health problem, consult your health care provider.